BRPI0614280A2 - atorvastatina sódica cristalina e amorfa - Google Patents

atorvastatina sódica cristalina e amorfa

Info

Publication number
BRPI0614280A2
BRPI0614280A2 BRPI0614280-0A BRPI0614280A BRPI0614280A2 BR PI0614280 A2 BRPI0614280 A2 BR PI0614280A2 BR PI0614280 A BRPI0614280 A BR PI0614280A BR PI0614280 A2 BRPI0614280 A2 BR PI0614280A2
Authority
BR
Brazil
Prior art keywords
crystalline
amorphous sodium
sodium atorvastatin
atorvastatin
amorphous
Prior art date
Application number
BRPI0614280-0A
Other languages
English (en)
Inventor
Kailan Zhou
Hong Liu
Zhirong Chen
Huabin Hong
Yang Sun
Yunde Wang
Jiangchun Pan
Original Assignee
Arrow Int Ltd
Zhejiang Neo Dankong Pharmaceu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CNB2005100603955A external-priority patent/CN100503564C/zh
Priority claimed from GB0613567A external-priority patent/GB0613567D0/en
Application filed by Arrow Int Ltd, Zhejiang Neo Dankong Pharmaceu filed Critical Arrow Int Ltd
Publication of BRPI0614280A2 publication Critical patent/BRPI0614280A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

ATORVASTATINA SóDICA CRISTALINA E AMORFA. A presente invenção se refere a atorvastatina sódica cristalina, composições contendo a mesma e métodos para a sua produção.
BRPI0614280-0A 2005-08-15 2006-08-14 atorvastatina sódica cristalina e amorfa BRPI0614280A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNB2005100603955A CN100503564C (zh) 2005-08-15 2005-08-15 高纯度结晶型阿伐他汀钠的制备方法
GB0613567A GB0613567D0 (en) 2006-07-07 2006-07-07 Crystalline sodium atorvastatin
PCT/GB2006/003035 WO2007020421A1 (en) 2005-08-15 2006-08-14 Crystalline and amorphous sodium atorvastatin

Publications (1)

Publication Number Publication Date
BRPI0614280A2 true BRPI0614280A2 (pt) 2009-08-04

Family

ID=36999969

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0614280-0A BRPI0614280A2 (pt) 2005-08-15 2006-08-14 atorvastatina sódica cristalina e amorfa

Country Status (7)

Country Link
US (2) US8017647B2 (pt)
EP (1) EP1924555B1 (pt)
CN (1) CN101268047B (pt)
AU (1) AU2006281237A1 (pt)
BR (1) BRPI0614280A2 (pt)
CA (1) CA2619040C (pt)
WO (1) WO2007020421A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006281229A1 (en) 2005-08-15 2007-02-22 Arrow International Limited Crystalline and amorphous sodium atorvastatin
BRPI0614280A2 (pt) * 2005-08-15 2009-08-04 Arrow Int Ltd atorvastatina sódica cristalina e amorfa
KR20120011249A (ko) 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
WO1994016693A1 (en) * 1993-01-19 1994-08-04 Warner-Lambert Company Stable oral ci-981 formulation and process of preparing same
SI1148049T1 (en) 1995-07-17 2005-02-28 Warner-Lambert Company Crystalline R-(R*,R*)$-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- (phenylamino)carbonyl -1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
US7411075B1 (en) * 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
DE60018100T2 (de) 1999-11-17 2005-09-15 Teva Pharmaceutical Industries Ltd. Polymorphe form von atorvastatin-calcium
CZ296967B6 (cs) 2002-02-01 2006-08-16 Zentiva, A.S. Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
CA2485722A1 (en) 2003-10-22 2005-04-22 Paul Lehmann Soluble transferrin receptor
WO2005073187A1 (en) 2004-01-28 2005-08-11 Apotex Pharmachem Inc. Improved process for the preparation of amorphous atorvastatin calcium
CA2666359A1 (en) 2004-03-17 2005-10-06 Yatendra Kumar Process for the production of atorvastatin calcium in amorphous form
CA2560282A1 (en) * 2004-03-17 2005-09-29 Ranbaxy Laboratories Limited Crystalline form of atorvastatin hemi calcium
US7875731B2 (en) * 2004-05-05 2011-01-25 Pfizer Inc. Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)Carbonyl]-1H-pyrrole-1-heptanoic acid
WO2006032959A2 (en) * 2004-08-06 2006-03-30 Glenmark Pharmaceuticals Limited Processes for the preparation of pyrrole derivatives
WO2006021969A1 (en) 2004-08-27 2006-03-02 Biocon Limited Process for atorvastatin calcium amorphous
GB2424880A (en) 2005-04-06 2006-10-11 Generics Crystalline forms of atorvastatin sodium, processes for their preparation and their use in inhibiting HMG-CoA reductase
BRPI0614280A2 (pt) * 2005-08-15 2009-08-04 Arrow Int Ltd atorvastatina sódica cristalina e amorfa
CN100484920C (zh) * 2005-08-15 2009-05-06 浙江新东港药业股份有限公司 高纯度阿伐他汀钙的制备方法
CN100503564C (zh) * 2005-08-15 2009-06-24 浙江新东港药业股份有限公司 高纯度结晶型阿伐他汀钠的制备方法
AU2006281229A1 (en) * 2005-08-15 2007-02-22 Arrow International Limited Crystalline and amorphous sodium atorvastatin

Also Published As

Publication number Publication date
EP1924555B1 (en) 2014-10-08
US8017647B2 (en) 2011-09-13
CN101268047B (zh) 2012-11-07
US20110218228A1 (en) 2011-09-08
CA2619040C (en) 2015-02-10
CA2619040A1 (en) 2007-02-22
US8440712B2 (en) 2013-05-14
WO2007020421A1 (en) 2007-02-22
AU2006281237A1 (en) 2007-02-22
CN101268047A (zh) 2008-09-17
EP1924555A1 (en) 2008-05-28
US20070066678A1 (en) 2007-03-22

Similar Documents

Publication Publication Date Title
NO20171775A1 (no) Ftalazinonderivat
CY1112467T1 (el) Παραγωγα 1-θειο-d-γλυκιτολης
MX2008001799A (es) Composicion farmaceutica que comprende un inhibidor de dipeptidil peptidasa iv.
NO20080784L (no) Histondeacetylaseinhibitorer
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
DK1959951T3 (da) Heteroaryl-substituerede piperidinderivater som L-CPT1-inhibitorer
HN2006014095A (es) Forma cristalina ortorrombica del maleato de asenapina
AU2008303600A8 (en) 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives
EP1943338A4 (en) Cell-free synthesis of membrane bound polypeptides
DE602006017133D1 (de) Doppelkupplungsgetriebe
EA200702586A1 (ru) Кристаллические модификации пираклостробина
ATE487691T1 (de) Acetylenderivate
EP1881975B8 (en) N,n-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors
DE502005003092D1 (de) Doppelkupplungsgetriebe
NO20074047L (no) Ny fremgangsmate for fremstilling av substituerte indoler
ATE523518T1 (de) Isomaltulose mit verbesserter fliessfähigkeit
MA32834B1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines
AR058253A1 (es) Procedimiento para la preparacion de ferri-succinilcaseina
NL1032046A1 (nl) Prostaglandinederivaten.
EA200801366A1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина
DK1931309T3 (da) Antimykotisk sammensætning
BRPI0720542A2 (pt) Compostos antibacterianos e processos para a sua produção
BRPI0614280A2 (pt) atorvastatina sódica cristalina e amorfa
MX2009003106A (es) Nueva modificacion cristalina de 4-(n-metil-2-cloro-5-piridilmetil amino)-2,5-dihidrofuran-2-ona.
EA200702428A1 (ru) Способы получения 4-бифенилилазетидин-2-онов

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: APRESENTE NOVAS VIAS DA TRADUCAO COMPLETA DO PEDIDO CONFORME DETERMINA O ITEM 15.3.3.10 ALINEA (B) DO ATO NORMATIVO NO 127 DE 05/03/1997.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2475 DE 12-06-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.